Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × ACE-011 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 4 Multiple Myeloma 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Small Cell Lung Carcinoma 1 Primary Myelofibrosis 1 Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 45 Bevacizumab 45 Cyclophosphamide 40 Carboplatin 37 Docetaxel 35 Fluorouracil 32 Cisplatin 32 Paclitaxel 31 pembrolizumab 28 Oxaliplatin 25 Radiotherapy 24 Irinotecan 23 Leucovorin 22 Capecitabine 22 Dexamethasone 21 Cetuximab 21 Nivolumab 19 Doxorubicin 19 Pemetrexed 18 Drug Therapy 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 13 Sorafenib 13 fludarabine 12 Lapatinib 12 Everolimus 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00931606 2023-09-13

MK-7962-012

Merck Sharp & Dohme LLC

Phase 2 Terminated

30 enrolled 32 charts

Classical hematology

Anemia, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡